# Pembrolizumab + MRGOO3 as Neoadjuvant in NPC

> **NCT07267338** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Union Hospital, Tongji Medical College, Huazhong University of Science and Technology** · enrollment: 35 (estimated)

## Conditions studied

- NPC
- Locoregionally Advanced Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** Pembrolizumab & MRG003

## Key facts

- **NCT ID:** NCT07267338
- **Lead sponsor:** Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2027-12
- **Final completion:** 2029-06
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2025-12-05

## Collaborators

- Merck Sharp & Dohme LLC
- Lepu Medical Technology (Beijing) Co., Ltd.

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07267338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07267338, "Pembrolizumab + MRGOO3 as Neoadjuvant in NPC". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT07267338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*